Investors Buy High Volume of Call Options on X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the recipient of unusually large options trading activity on Tuesday. Stock traders purchased 9,665 call options on the stock. This is an increase of approximately 3,751% compared to the average volume of 251 call options.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Stifel Nicolaus decreased their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright decreased their target price on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

Shares of XFOR traded up $0.01 during midday trading on Tuesday, reaching $0.53. The stock had a trading volume of 3,939,884 shares, compared to its average volume of 2,350,655. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The firm’s 50 day moving average price is $0.48 and its 200-day moving average price is $0.67. The company has a market capitalization of $91.04 million, a P/E ratio of -5.86 and a beta of 0.35.

Insider Buying and Selling

In other news, COO Mary Dibiase sold 67,695 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at approximately $257,674.20. This trade represents a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $131,689.80. Following the sale, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. The trade was a 18.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock valued at $321,447 in the last quarter. Company insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth $37,000. Ensign Peak Advisors Inc grew its holdings in shares of X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after buying an additional 111,032 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares in the last quarter. K2 Principal Fund L.P. purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at $284,000. Finally, XTX Topco Ltd purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at $65,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.